TrialLeukemia2023

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.

Jan Philipp Bewersdorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.